



## OptimizeRx Named to LD Micro's "Hall of Fame" As One of the Top 50 Performing Companies

June 1, 2021

ROCHESTER, Mich., June 01, 2021 (GLOBE NEWSWIRE) -- [OptimizeRx Corp.](#) (the "Company") (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, announced today that Will Febbo, OptimizeRx's CEO, will participate in the LD Micro Virtual Invitational (XI) conference on June 8, 2021. OptimizeRx will be inducted into LD Micro's "Hall of Fame", ranked number 36 of 50. The LD Micro Hall of Fame list highlights the top 50 best performing companies out of over 2,000 companies which have attended prior LD Micro conferences.

The live webcast and replay of the presentation will be made available on the day of the event at [investors.optimizerx.com/events-and-presentations](https://investors.optimizerx.com/events-and-presentations).

### Conference details (LD Micro Virtual Invitational (XI))

**Date:** Tuesday, June 8  
**Time:** 3:00-3:25 PM ET  
**Track:** Track 1

LD Micro's three-day virtual investor conference will feature around 180 companies presenting for 25 minutes each and several influential keynotes.

You can register for the event here: <https://ldmicrojune2021.mysequire.com>.

### About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on [Twitter](#), [LinkedIn](#) or visit [www.optimizerx.com](http://www.optimizerx.com).

### Important Cautions Regarding Forward-Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and in section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

### OptimizeRx Contact

Doug Baker, CFO  
Tel (248) 651-6568 x807  
[dbaker@optimizerx.com](mailto:dbaker@optimizerx.com)

### Media Relations Contact

Maira Alejandra, Media Relations Manager  
Tel (754) 245-7070  
[malejandra@optimizerx.com](mailto:malejandra@optimizerx.com)

### Investor Relations Contact

Ashley Robinson  
LifeSci Advisors, LLC  
[arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)



Source: OptimizeRx Corporation